Just one contract (0.5 per cent) was published without redactions. Of the handful of contracts that had been published, almost all include significant redactions of key information such as total price paid, price per dose and delivery schedules.Īnalysis of 183 contracts for 12 different COVID-19 vaccines reveals that only 7 per cent of vaccine contracts between developers and governments were published through official channels. The research also highlights poor transparency in contracts between drug companies and governments. The lack of publicly accessible data creates space for misleading and potentially dangerous half-truths, disinformation, and conspiracy theories, which in turn contribute to vaccine hesitancy.” The lack of transparency of many clinical trials combined with the huge financial incentives for producing effective treatments leaves the door wide open for selective reporting of results or outright data manipulation. Jonathan Cushing, Head of Transparency International’s Global Health Programme, said: “These results make for worrying reading and carry important implications not just for the COVID-19 response, but also for future health emergencies. There were no publicly accessible protocols for 88 per cent of the registered trials in our analysis and, therefore, no way of knowing the conditions under which they were carried out. Of this figure, 41 per cent had provided only top-level results via a press release or press conference, with the full data not made available for media scrutiny or academic review.Ĭlinical trial protocols had been published for just 12 per cent of trials. Despite this, analysis of the registered clinical trials for the top vaccines reveals that results from just 45 per cent of these trials had been announced. Read the report | Read the policy brief in English or Spanish | Read the press release in SpanishĬlinical trial transparency is the only way to monitor the safety and efficacy of vaccines and is a key safeguard against selective reporting of results or manipulation of data. Through detailed analysis of clinical trial data and nearly 200 contracts for vaccine sales up to March 2021, the report reveals a pattern of poor transparency and a disturbing trend of governments censoring key details of their orders from drug companies. A lack of transparency in COVID-19 vaccine trials and secrecy over deals between governments and drug companies risks the success of the global pandemic response, new research from Transparency International Global Health and the University of Toronto warns.įor Whose Benefit? is an in-depth study of the development and sale of the world’s top 20 COVID-19 vaccines, including those developed by AstraZeneca, Moderna and Pfizer/BioNTech.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |